Table 4B. Complications of treatment.
Bevacizumab group (n=64) | Non-bevacizumab group (n=99) | P-valuea | |
---|---|---|---|
Retinal detachment | 2 (3%) | 0 | 0.15 |
Cataract | 0 | 3 (3%) | 0.28 |
Hyphema | 19 (30%) | 8 (8%) | <0.001 |
Tube erosion | 0 | 1 (1%) | 1.00 |
Data are presented as number (percentage).
Two-sample Wilcoxon test.